# Durvalumab

Source: https://onco.cc/drugs/durvalumab/  
OnCo record `durvalumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A PD-L1 blocker that became standard after chemoradiation for stage III lung cancer, and now in bladder, biliary, and gastric cancers.

## Summary

PACIFIC (unresectable stage III NSCLC), ADRIATIC (limited-stage SCLC, 2024), TOPAZ-1 (biliary tract), HIMALAYA (HCC with tremelimumab), NIAGARA (perioperative muscle-invasive bladder cancer, 2025), MATTERHORN (perioperative gastric, 2025), and Q2 2026 high-risk non-muscle-invasive bladder cancer with BCG (POTOMAC). Partner of Dato-DXd in TROPION-Breast05.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-04
- Brand: Imfinzi
- Modality: Monoclonal antibody (anti-PD-L1)
- Mechanism: Human IgG1 anti-PD-L1 with reduced Fc effector function.
- Approvals: US 2017: Locally advanced or metastatic urothelial carcinoma after platinum (accelerated; indication withdrawn 2021); US 2018: Unresectable stage III NSCLC after chemoradiation; US 2022: Locally advanced or metastatic biliary tract cancer (gallbladder cancer included) with gemcitabine and cisplatin (TOPAZ-1); UK 2024: Locally advanced, unresectable or metastatic biliary tract cancer with gemcitabine and cisplatin; NICE TA944 recommended 10 January 2024 with a commercial arrangement; US 2026: High-risk NMIBC with BCG; England (NICE) 2022: Locally advanced unresectable non-small-cell lung cancer with PD-L1 on 1 percent or more of cells that has not progressed after concurrent platinum-based chemoradiation; England (NICE) 2025: Untreated extensive-stage small-cell lung cancer, with etoposide and either carboplatin or cisplatin; England (NICE) 2025: Resectable non-small-cell lung cancer (4 cm or more, or node positive) without an EGFR mutation or ALK rearrangement, neoadjuvant with platinum chemotherapy then adjuvant alone; England (NICE) 2025: Limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy
- Dosing: IV infusion; 10 mg/kg every 2 weeks or 1,500 mg every 4 weeks (≥30 kg); up to 12 months after chemoradiation in stage III NSCLC

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Durvalumab
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Durvalumab
- NICE TA798: durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation: https://www.nice.org.uk/guidance/ta798
- NICE TA1030: durvalumab with chemotherapy before surgery then alone after surgery for resectable non-small-cell lung cancer: https://www.nice.org.uk/guidance/ta1030
- NICE TA1041: durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer: https://www.nice.org.uk/guidance/ta1041
- NICE TA1099: durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy: https://www.nice.org.uk/guidance/ta1099

## Connected records

- cancers: [Advanced hepatocellular carcinoma (BCLC C)](https://onco.cc/cancers/hcc-advanced/), [Advanced or recurrent endometrial cancer](https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/), [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Cystic duct carcinoma](https://onco.cc/cancers/cystic-duct-carcinoma/), [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Extrapulmonary neuroendocrine carcinoma](https://onco.cc/cancers/extrapulmonary-nec/), [Gallbladder adenocarcinoma](https://onco.cc/cancers/gallbladder-adenocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Incidental gallbladder cancer (found after cholecystectomy)](https://onco.cc/cancers/incidental-gallbladder-cancer/), [Intermediate hepatocellular carcinoma (BCLC B)](https://onco.cc/cancers/hcc-intermediate/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/), [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Microsatellite-unstable (MSI-high) gastric cancer](https://onco.cc/cancers/gastric-msi-high/), [Mismatch-repair-deficient endometrial cancer](https://onco.cc/cancers/endometrial-mmr-deficient/), [Muscle-invasive and advanced bladder cancer](https://onco.cc/cancers/muscle-invasive-bladder-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high gastric cancer](https://onco.cc/cancers/gastric-pdl1-high/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Immune endocrine damage is usually permanent, and almost nobody is told](https://onco.cc/technologies/rejuv-recovery-endocrine-permanence/)
- targets: [NKG2A (KLRC1)](https://onco.cc/targets/klrc1/), [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [German Breast Group (GBG)](https://onco.cc/companies/gbg/)
- trials: [A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer](https://onco.cc/trials/nct04538742/), [A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.](https://onco.cc/trials/nct07679399/), [A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement](https://onco.cc/trials/nct06728410/), [A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07269158/), [A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer](https://onco.cc/trials/nct06112379/), [A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small](https://onco.cc/trials/nct07005128/), [A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C](https://onco.cc/trials/nct05170204/), [A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition](https://onco.cc/trials/nct05061134/), [A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors](https://onco.cc/trials/nct02671435/), [A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)](https://onco.cc/trials/nct03459846/), [A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients](https://onco.cc/trials/nct03706690/), [A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma](https://onco.cc/trials/nct02519348/), [A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer](https://onco.cc/trials/nct07174583/), [A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06667908/), [A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC](https://onco.cc/trials/nct07459634/), [A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct03800134/), [A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct03742102/), [A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)](https://onco.cc/trials/nct07221253/), [A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07672223/), [A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell](https://onco.cc/trials/nct07361497/), [A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv](https://onco.cc/trials/nct06780137/), [A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment](https://onco.cc/trials/nct06746116/), [A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negat](https://onco.cc/trials/nct06508216/), [A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy](https://onco.cc/trials/nct05941897/), [A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small ](https://onco.cc/trials/nct06606847/), [A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS](https://onco.cc/trials/nct06008093/), [A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat](https://onco.cc/trials/nct06040099/), [ABC-12](https://onco.cc/trials/abc-12/), [ADRIATIC](https://onco.cc/trials/adriatic/), [AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06591520/), [Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma](https://onco.cc/trials/nct07780838/), [An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC](https://onco.cc/trials/nct07720284/), [Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment](https://onco.cc/trials/nct03847428/), [BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants](https://onco.cc/trials/nct05943106/), [Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati](https://onco.cc/trials/nct07195695/), [Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies](https://onco.cc/trials/nct03539822/), [CALLA](https://onco.cc/trials/calla/), [CASPIAN](https://onco.cc/trials/caspian/), [COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC](https://onco.cc/trials/nct04068610/), [Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma](https://onco.cc/trials/nct03937830/), [Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for The](https://onco.cc/trials/nct05927142/), [Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer](https://onco.cc/trials/nct01993810/), [Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)](https://onco.cc/trials/nct06502080/), [CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers](https://onco.cc/trials/nct06548412/), [DEBATE](https://onco.cc/trials/debate/), [DeLLphi-305](https://onco.cc/trials/dellphi-305/), [DIAMOND](https://onco.cc/trials/diamond/), [DREAM3R](https://onco.cc/trials/dream3r/), [DUO-E / GOG-3041 / ENGOT-EN10](https://onco.cc/trials/duo-e/), [DUO-O / ENGOT-ov46](https://onco.cc/trials/duo-o/), [Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer](https://onco.cc/trials/nct03482102/), [Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.](https://onco.cc/trials/nct06992609/), [Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)](https://onco.cc/trials/nct04597671/), [Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)](https://onco.cc/trials/nct05883644/), [Durvalumab and Tremelimumab for Pediatric Malignancies](https://onco.cc/trials/nct03837899/), [Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer](https://onco.cc/trials/nct04499053/), [Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)](https://onco.cc/trials/nct05451043/), [Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma](https://onco.cc/trials/nct07081633/), [Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer](https://onco.cc/trials/nct05640791/), [Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC](https://onco.cc/trials/nct06490107/), [Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC](https://onco.cc/trials/nct05557838/), [Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)](https://onco.cc/trials/nct05771480/), [Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation](https://onco.cc/trials/nct03833154/), [EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer](https://onco.cc/trials/ea2197-ivonescimab/), [Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ](https://onco.cc/trials/nct06463665/), [Efficacy and Safety of CRT, Durvalumab and Surgery for SST](https://onco.cc/trials/nct04465968/), [EMERALD-1](https://onco.cc/trials/emerald-1/), [EMERALD-3](https://onco.cc/trials/emerald-3/), [Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07710885/), [Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer](https://onco.cc/trials/nct06591650/), [GEMSTONE-301](https://onco.cc/trials/gemstone-301/), [HIMALAYA](https://onco.cc/trials/himalaya/), [I-SPY 2](https://onco.cc/trials/i-spy-2/), [Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial](https://onco.cc/trials/nct06498635/), [Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)](https://onco.cc/trials/nct04238637/), [IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)](https://onco.cc/trials/nct05742607/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/), [Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens](https://onco.cc/trials/nct06419179/), [MATTERHORN](https://onco.cc/trials/matterhorn/), [MERMAID-1](https://onco.cc/trials/mermaid-1/), [MERMAID-2](https://onco.cc/trials/mermaid-2/), [MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer](https://onco.cc/trials/nct05903092/), [MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma](https://onco.cc/trials/nct07036380/), [National Lung Matrix Trial](https://onco.cc/trials/national-lung-matrix-trial/), [Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct05061550/), [NIAGARA](https://onco.cc/trials/niagara/), [Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy](https://onco.cc/trials/nct05222971/), [PACIFIC](https://onco.cc/trials/pacific/), [PACIFIC-2](https://onco.cc/trials/pacific-2/), [Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma](https://onco.cc/trials/nct06530823/), [Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)](https://onco.cc/trials/nct06960577/), [Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC](https://onco.cc/trials/nct04585490/), [Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)](https://onco.cc/trials/nct04379596/), [Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)](https://onco.cc/trials/nct03944772/), [Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer](https://onco.cc/trials/nct06467357/), [Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06708858/), [Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy](https://onco.cc/trials/nct03334617/), [Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct02453282/), [Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations](https://onco.cc/trials/nct05687266/), [PHOENIX DDR/Anti-PD-L1](https://onco.cc/trials/phoenix/), [POTOMAC](https://onco.cc/trials/potomac/), [Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)](https://onco.cc/trials/nct05845450/), [QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors](https://onco.cc/trials/nct03228667/), [RAINBO](https://onco.cc/trials/rainbo/), [REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)](https://onco.cc/trials/nct05632809/), [Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel](https://onco.cc/trials/nct05582538/), [RUGB](https://onco.cc/trials/rugb/), [Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer](https://onco.cc/trials/nct06274879/), [Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours](https://onco.cc/trials/nct04999969/), [Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct05374603/), [Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC](https://onco.cc/trials/nct05043090/), [Single cEll pRofiling PErsistaNce To ImmuNothErapy](https://onco.cc/trials/nct06680739/), [Study of AZD2811 + Durvalumab in ES-SCLC](https://onco.cc/trials/nct04745689/), [Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).](https://onco.cc/trials/nct03164616/), [Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)](https://onco.cc/trials/nct03003962/), [Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer](https://onco.cc/trials/nct03682068/), [Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC](https://onco.cc/trials/nct04550260/), [Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)](https://onco.cc/trials/nct02542293/), [Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)](https://onco.cc/trials/nct03775486/), [Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer](https://onco.cc/trials/nct02516241/), [Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer](https://onco.cc/trials/nct05498155/), [Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06890598/), [Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC](https://onco.cc/trials/nct05733598/), [Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct07339059/), [Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,](https://onco.cc/trials/nct05925530/), [Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer](https://onco.cc/trials/nct07637513/), [Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti](https://onco.cc/trials/nct04092283/), [Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct03606967/), [Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06732401/), [Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05624996/), [The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer](https://onco.cc/trials/nct05422690/), [The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers](https://onco.cc/trials/nct04781192/), [The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2](https://onco.cc/trials/nct07146230/), [TheraSphere With Durvalumab and Tremelimumab for HCC](https://onco.cc/trials/nct05063565/), [TOPAZ-1](https://onco.cc/trials/topaz-1/), [Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin](https://onco.cc/trials/nct04960709/), [Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors](https://onco.cc/trials/nct05187338/), [TROPION-Breast03](https://onco.cc/trials/tropion-breast03/), [TROPION-Breast05](https://onco.cc/trials/tropion-breast05/), [WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC](https://onco.cc/trials/nct04644289/)
- people: [Anna K. Nowak](https://onco.cc/people/anna-nowak/), [Do-Youn Oh](https://onco.cc/people/oh-do-youn/), [Ghassan K. Abou-Alfa](https://onco.cc/people/ghassan-abou-alfa/), [John V. Heymach](https://onco.cc/people/john-heymach/), [Juan W. Valle](https://onco.cc/people/juan-valle/), [Lajos Pusztai](https://onco.cc/people/lajos-pusztai/), [Scott J. Antonia](https://onco.cc/people/scott-antonia/), [Sibylle Loibl](https://onco.cc/people/sibylle-loibl/), [Thomas Powles](https://onco.cc/people/thomas-powles/)
- drugs: [Tremelimumab](https://onco.cc/drugs/tremelimumab/), [VENTANA PD-L1 (SP263) Assay](https://onco.cc/drugs/ventana-pd-l1-sp263/)
- pairings: [Caution: bevacizumab-based regimens with untreated varices](https://onco.cc/pairings/io-varices-caution/), [Caution: DXd ADC + agents with pneumonitis risk](https://onco.cc/pairings/ild-overlap-caution/), [Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer](https://onco.cc/pairings/chemo-io-first-line-endometrial/), [Durvalumab + BCG in BCG-naive high-risk NMIBC](https://onco.cc/pairings/durvalumab-plus-bcg/), [PD-1 blockade + chemotherapy in PD-L1-low NSCLC](https://onco.cc/pairings/pd1-plus-chemo-pdl1-low/), [Radiotherapy + immunotherapy](https://onco.cc/pairings/radiation-plus-io/)
- ideas: [A ctDNA residual disease-guided adjuvant trial after gallbladder cancer resection](https://onco.cc/ideas/idea-gbc-ctdna-residual-disease-guided-adjuvant-trial/), [A neutral platform trial for radiotherapy plus immunotherapy combinations](https://onco.cc/ideas/idea-fund-rt-io-platform/), [Chemotherapy before the second operation for high-risk incidental gallbladder cancer](https://onco.cc/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/), [Molecular-class-directed adjuvant therapy in endometrial cancer](https://onco.cc/ideas/idea-molecular-class-adjuvant-endometrial/)
- key papers: [ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer](https://onco.cc/key-papers/paper-adriatic-nejm-2024/), [DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer](https://onco.cc/key-papers/paper-duo-e-jco-2023/), [Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study](https://onco.cc/key-papers/paper-topaz-1-three-year-survival-j-hepatol-2025/), [Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)](https://onco.cc/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/), [Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial](https://onco.cc/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/), [EMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma](https://onco.cc/key-papers/paper-emerald-1-lancet-2025/), [Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer](https://onco.cc/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/), [HIMALAYA: tremelimumab plus durvalumab in unresectable hepatocellular carcinoma](https://onco.cc/key-papers/paper-himalaya-nejm-evidence-2022/), [MATTERHORN: perioperative durvalumab with FLOT chemotherapy for resectable gastric and gastro-oesophageal junction cancer](https://onco.cc/key-papers/paper-matterhorn-nejm-2025/), [NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer](https://onco.cc/key-papers/paper-niagara-nejm-2024/), [Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC](https://onco.cc/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/), [PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer](https://onco.cc/key-papers/paper-pacific-nejm-2017/), [Perioperative durvalumab for resectable non-small-cell lung cancer](https://onco.cc/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/), [TOPAZ-1: durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer](https://onco.cc/key-papers/paper-topaz-1-nejm-evidence-2022/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/), [Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH](https://onco.cc/roadmaps/radiation-roadmap/)
- terms: [Consolidation therapy](https://onco.cc/terms/consolidation-therapy/), [Immune checkpoint](https://onco.cc/terms/immune-checkpoint/), [Immuno-oncology (IO) and checkpoint blockade](https://onco.cc/terms/immuno-oncology/), [Limited-stage vs extensive-stage (small-cell lung cancer)](https://onco.cc/terms/limited-extensive-stage/), [Lung cancer drugs in England: what NICE has recommended](https://onco.cc/terms/lung-uk-drug-access/), [Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11](https://onco.cc/terms/sclc-molecular-subtypes/)
- pathways: [Bladder cancer (KEGG map)](https://onco.cc/pathways/bladder-cancer-signalling/), [Endometrial cancer (KEGG map)](https://onco.cc/pathways/endometrial-cancer-signalling/), [Hepatocellular carcinoma (KEGG map)](https://onco.cc/pathways/hepatocellular-carcinoma-signalling/), [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [Small cell lung cancer (KEGG map)](https://onco.cc/pathways/sclc-signalling/)
- bottlenecks: [No one can predict who responds to immunotherapy](https://onco.cc/bottlenecks/b-immunotherapy-response/)
- institutions: [Hospital Universitario 12 de Octubre](https://onco.cc/institutions/12-de-octubre/), [IRCCS Humanitas Research Hospital](https://onco.cc/institutions/humanitas/)
- biomarkers: [dMMR (mismatch repair deficiency by IHC)](https://onco.cc/biomarkers/dmmr-ihc/)

---
JSON: https://onco.cc/api/v1/entities/durvalumab.json